2009
DOI: 10.1158/0008-5472.sabcs-3137
|View full text |Cite
|
Sign up to set email alerts
|

A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer.

Abstract: #3137 Background: The epitholones are a new class of antineoplastic agents which are microtubule inhibitors with low susceptibility to several mechanisms of drug resistance. Ixabepilone (BMS-247550, aza-epothilone B) has demonstrated efficacy as monotherapy or in combination with capecitabine (in anthracycline- and taxane-pretreated metastatic breast cancer) and has recently been approved for use in refractory breast cancer. A multicenter NCI-sponsored study was conducted to analyze the safety a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0
1

Year Published

2009
2009
2017
2017

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 13 publications
(6 citation statements)
references
References 0 publications
0
5
0
1
Order By: Relevance
“…The median age of patients was 51 and a median of seven cycles of therapy were administered in each cohort. Ixabepilone plus trastuzumab produced an ORR of 51% (clinical benefit rate 56%) and median age a median TTP of 6.1 months [ 57 ].…”
Section: Ixabepilone and Targeted Therapy Combinationsmentioning
confidence: 99%
“…The median age of patients was 51 and a median of seven cycles of therapy were administered in each cohort. Ixabepilone plus trastuzumab produced an ORR of 51% (clinical benefit rate 56%) and median age a median TTP of 6.1 months [ 57 ].…”
Section: Ixabepilone and Targeted Therapy Combinationsmentioning
confidence: 99%
“… 61 Additionally, an overall response rate of 53.8% was reported for ixabepilone in combination with trastuzumab in patients with HER2-positive metastatic breast cancer. 62 The results of additional trials examining ixabepilone combination therapy in patients with MBC are anticipated in 2009.…”
Section: Discussionmentioning
confidence: 99%
“…The primary endpoint was the RR in each cohort. Preliminary results have been reported for 39 patients, including 15 patients in cohort 1 and 24 in cohort 2 [Tolaney et al 2008]. The ORR for the entire study population was 51.3%, with a substantially higher rate in cohort 1 compared with cohort 2 (80.0% versus 33.3%).…”
Section: Overview Of Preclinical Studies Of Ixabepilone Monotherapymentioning
confidence: 94%